The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an ...

The company reported a Q4 EPS of $0.15, which was $0.07 higher than the analyst estimate of $0.08. Revenue for the quarter came in at $108.19 million, outpacing the consensus estimate of $97.66 ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall ...

Hospital-based care for hallucinogen use is associated with increased mortality, according to a study published online March ...

European equities traded in the US as American depositary receipts kicked off the week on strong note late Monday morning, surging 1.83% higher to 1,442.61 on the S&P Europe Select ADR Index. From ...

LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following inve ...

Syndax Pharmaceuticals Inc. (SNDX) ...

Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) has been given a consensus recommendation of “Hold” by the nineteen ratings firms that are currently covering the stock, MarketBeat.com reports.